You are here: Industry Insights > Kite Pharma

News List

Kite Pharma Expands Mfg. Facility in MD contractpharma
April 28, 2019
Kite Pharma, a Gilead company, plans to expand manufacturing capacity with a new biologics facility in Urbana, MD. Kite specializes in cancer treatments and is expanding its ability to provide both clinical and commercial treatments.
2018: Gilead is Not Done Shopping biospace
January 11, 2018
One of last year’s big stories was Gilead Sciences acquiring Kite Pharma for about $11.9 billion in late August.
Gilead to Acquire Kite Pharma for $11.9B contractpharma
September 05, 2017
Gilead Sciences has entered an agreement to acquire Kite Pharma, a cell therapy company headquartered in Santa Monica, CA, for approximately $11.9 billion. The transaction, subject to customary closing conditions, is expected to close 4Q17.
How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight fiercepharma
August 30, 2017
Gilead announced an $11.9 purchase of Kite Pharma on Monday, picking up the promising CAR-T drug Axi-Cel.
Gilead Sciences to acquire Kite Pharma for $11.9 Billion biospectrumasia
August 30, 2017
Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA)
Gilead Sciences to buy Kite Pharma for $11.9bn pharmaceutical-technology
August 30, 2017
Biopharmaceutical company Gilead Sciences has entered a definitive agreement to acquire US-based Kite Pharma for approximately $11.9bn.
Kite Pharma submits MAA for axicabtagene ciloleucel in Europe pharmaceutical-technology
August 03, 2017
US-based cell therapy company Kite Pharma has filed a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for axicabtagene ciloleucel.
Kite Pharma climbs on strong data showing in lymphoma trial pharmafile
March 02, 2017
Kite Pharma released the news on Rare Diseases Day promising top-line data from a Phase 1/2 trial of its treatment for various types of non-Hodgkin lymphoma.
Kite Pharma reports positive six-month data for CAR-T therapy in non-Hodgkin lymphoma firstwordpharma
March 01, 2017
Kite Pharma on Tuesday reported positive six-month results from a mid-stage study investigating its experimental CAR-T therapy axicabtagene ciloleucel in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma.
Kite Pharma joins hands with Daiichi Sankyo for cancer med biospectrumasia
January 11, 2017
Daiichi Sankyo will make an upfront payment to Kite of $50 million and Kite will be eligible to receive future payments totaling up to $200 million for development and commercial milestones